Forte Biosciences (FBRX) Total Current Liabilities (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Total Current Liabilities data on file, last reported at $23.6 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 161.81% year-over-year to $23.6 million in Q1 2026; TTM through Mar 2026 was $23.6 million, a 161.81% increase from a year earlier, with the FY2025 full-year figure at $20.8 million, up 128.51% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $23.6 million, up from $20.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for FBRX reached as high as $23.6 million in Q1 2026 and fell as low as $1.3 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $7.9 million across 5 years, with a median of $7.5 million in 2023.
• Across the five-year window, Total Current Liabilities sank 49.19% in 2022 and surged 316.39% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $3.2 million in 2022, then increased by 15.32% to $3.7 million in 2023, then surged by 147.71% to $9.1 million in 2024, then soared by 128.51% to $20.8 million in 2025, then rose by 13.96% to $23.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $23.6 million in Q1 2026, $20.8 million in Q4 2025, and $13.0 million in Q3 2025.